Amgen, Inc. vs Peloton Interactive Inc — how do they compare? Amgen, Inc. trades at $415.21 (market cap $224.14B), while Peloton Interactive Inc trades at $5.46 (market cap $2.46B). The key difference: Amgen, Inc. is far larger — about 91.1× Peloton Interactive Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Peloton Interactive Inc pays none. Which is the better fit depends on your goals.
| AMGN | PTON | |
|---|---|---|
Market Cap | $224.14B | $2.46B |
Sector | Health | Consumer Cyclical |
52-Week High | $417.20 | $9.00 |
52-Week Low | $271.18 | $3.71 |
Enterprise Value | $267.45B | $2.96B |
Dividend Yield | 2.43% | — |
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
Peloton Interactive (PTON) trades at $5.51, down 2.99% on the day, reflecting ongoing investor caution despite achieving its first annual net profit in fiscal 2026. The stock shows a bearish technical trend with key support at $5, while fundamentals reveal a mixed picture: revenue declined to $2.49B in 2025 but net losses narrowed significantly, with a positive net income margin of 2.58% projected for 2026. Recent news highlights profitability milestones but also subscriber declines and a conservative 2027 outlook.
The outlook remains cautious; profitability improvements and cost control are positive, but persistent revenue erosion and high debt levels pose risks. Analyst sentiment is divided with a 50% buy rating, yet the stock's proximity to support levels suggests potential for stability if execution continues. Key risks include subscriber retention and competitive pressures in the fitness market.
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →